XGN (Exagen) Common Stock: $0.02 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XGN Exagen Inc XGN
63 GF Score
Price $4.09
GF Value $3.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exagen Common Stock?

Exagen XGN -1.45% 63 Common Stock is $0.02 Mil as of Mar. 2026. GuruFocus rates XGN with a GF Score™ of 63/100 and a GF Value™ of $3.00 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Exagen's quarterly common stock stayed the same from Sep. 2025 ($0.02 Mil) to Dec. 2025 ($0.02 Mil) but then increased from Dec. 2025 ($0.02 Mil) to Mar. 2026 ($0.02 Mil).

Exagen's annual common stock increased from Dec. 2023 ($0.02 Mil) to Dec. 2024 ($0.02 Mil) and increased from Dec. 2024 ($0.02 Mil) to Dec. 2025 ($0.02 Mil).

Exagen Common Stock Historical Data

* Premium members only.

The historical data trend for Exagen's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exagen Common Stock Chart

Exagen Annual Data
Trend Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

Exagen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02
XGN
63GF Score
Exagen Inc XGN
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Exagen Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.02 Mil mean?
Exagen (XGN) has a Common Stock of $0.02 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Exagen and its competitors.
Is Exagen's Common Stock too high?
Exagen's current Common Stock is $0.02 Mil. Overall, Exagen has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exagen's Common Stock compare to BNR and IMDX?
Exagen's Common Stock of $0.02 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Diagnostics & Research company?
A good Common Stock depends on the Medical Diagnostics & Research industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Exagen and its competitors. Exagen's current Common Stock is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exagen stock overvalued right now?
Based on GuruFocus' analysis, Exagen (XGN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $4.09 — trading 36.3% above its estimated fair value. The current Common Stock is $0.02 Mil. Exagen's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Exagen (XGN), the current Common Stock is $0.02 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exagen (XGN) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of $4.09 is trading 36.3% above its estimated GF Value™ of $3.00. GuruFocus considers Exagen to be Significantly Overvalued.

Key valuation signals for XGN:

  • Common Stock: $0.02 Mil
  • GF Value™: $3.00 vs. price of $4.09 (36.3% above fair value)
  • GF Score™: 63/100 with 3 warning signs

No single metric tells the full story. See the XGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exagen Business Description

Other Exchanges E08A:Germany
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
63GF Score

Get the complete analysis for XGN

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.09
Price
$3.00
GF Value